- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02405897
A Study to Evaluate the Efficacy and Safety of Fenestrated Cup Forceps Versus Fenestrated Alligator Forceps for Performing Transbronchial Lung Biopsy in Patients With Sarcoidosis
January 2, 2017 updated by: Ritesh Agarwal, Postgraduate Institute of Medical Education and Research
Sarcoidosis is a systemic disease that results from granulomatous inflammation that involves multiple body organs.
The diagnosis requires the presence of compatible clinicoradiological features along with histologic evidence that demonstrates non-caseating.1 Mediastinal lymph nodes and the lung parenchyma are the most commonly involved structures in sarcoidosis that can be sampled by, performing various bronchoscopic techniques.
In a recent study the use of alligator forceps had a better yield in comparison to cup forceps.
The investigators hypothesize that use of fenestrated alligator forceps in comparison to fenestrated cup forceps will yield larger samples, thereby improving the diagnostic yield and reducing the number of biopsy samples irrespective of the stage of sarcoidosis.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Sarcoidosis is a multisystem disorder characterized by granulomatous inflammation involving various body organs.
The diagnosis is based on presence of fulfillment of compatible clinicoradiological features and histologic evidence of non-caseating granuloma after exclusion of other known causes for granulomatous inflammation.1
As the lung and mediastinal lymph nodes are the most commonly involved structures in sarcoidosis, performing various bronchoscopic techniques like endobronchial biopsy (EBB), transbronchial biopsy (TBLB) and transbronchial needle aspiration (TBNA) are needed for tissue sampling.
The diagnostic yield of TBLB in sarcoidosis in stage I and II varies from 31%2 to 69.6%.3
Transbronchial lung biopsy (TBLB) is performed with flexible bronchoscopy under the effect of local anesthesia and is the most commonly used bronchoscopic procedure to diagnose a wide array of lung diseases.
It is performed as an outpatient procedure and is associated with minimal complications such as bleeding, pneumothorax and others.4
The procedure can be performed either as a blindly or under fluoroscopic guidance.
The yield of TBLB varies depending upon the extent of disease, size of tissue, number of alveoli, number of biopsies, whether the sample floats or not and the size of forceps.5-12
The diagnostic yield of TBLB in sarcoidosis depends on the radiological stage and varies from 50-65% in stage I to 80 to 85% in stage II.13-15
The diagnostic yield also depends on the number of biopsy specimens (ten in stage I and 4-6 in stage II and III).9,10
In a recent study comprising of 44 patients with 176 samples, the use of alligator forceps yielded larger samples with lesser incidence of complications (major bleeding, alligator v/s cup forceps respectively, 1% v/s 5.7% and pneumothorax, 4.5 %v/s 9.1%).
The investigators hypothesize that use of fenestrated alligator forceps in comparison to fenestrated cup forceps will yield larger samples, thereby improving the diagnostic yield and reducing the number of biopsy samples irrespective of the stage of sarcoidosis.
Study Type
Interventional
Enrollment (Actual)
150
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Chandigarh, India, 160012
- Bronchoscopy suite, PGIMER
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
12 years to 90 years (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- patients with a clinical diagnosis of sarcoidosis undergoing flexible bronchoscopy
- age group of 12 to 90 years;
- hemodynamically stable (systolic BP > 100 mm Hg without the need of vasopressors); and
- ability to provide informed consent to participate in the study.
Exclusion Criteria:
- hemoglobin less than 8 gm/dL;
- platelet count of less than 80000;
- bleeding diathesis;
- prothrombin time or activated partial thrombin time prolongation of more than 6 seconds when compared to control;
- baseline room air saturation less than 90%;
- pregnancy; and,
- failure to provide informed consent.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Cup forceps
4 biopsies (transbronchial lung biopsy) with Cup forceps
|
In patients with sarcoidosis, flexible bronchoscopy and transbronchial lung biopsy using cup forceps
|
|
Active Comparator: Alligator forceps
4 biopsies (transbronchial lung biopsy) with Alligator forceps
|
In patients with sarcoidosis, flexible bronchoscopy and transbronchial lung biopsy using alligator forceps
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Diagnostic yield of fenestrated alligator versus fenestrated cup forceps for transbronchial lung biopsy (Size of the tissue)
Time Frame: 12 months
|
Size of tissue: Size of the tissue will be visually assessed as small if it does not fill the cup, medium if it fills the cup and large if comes out of the cup
|
12 months
|
|
Diagnostic yield of fenestrated alligator versus fenestrated cup forceps for transbronchial lung biopsy (Size of the tissue)
Time Frame: 12 months
|
Size of tissue in millimeters during histopathology
|
12 months
|
|
Diagnostic yield of fenestrated alligator versus fenestrated cup forceps for transbronchial lung biopsy (histopathology)
Time Frame: 12 months
|
Histopathology examination and findings
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Complication (Occurrence of bleeding)
Time Frame: 12 months
|
Occurrence of bleeding
|
12 months
|
|
Complication (Occurrence of pneumothorax)
Time Frame: 12 months
|
Occurrence of pneumothorax
|
12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Ritesh Agarwal, MD, DM, PGIMER, Chandigarh
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2015
Primary Completion (Actual)
November 1, 2015
Study Completion (Actual)
December 1, 2015
Study Registration Dates
First Submitted
March 23, 2015
First Submitted That Met QC Criteria
March 31, 2015
First Posted (Estimate)
April 1, 2015
Study Record Updates
Last Update Posted (Estimate)
January 4, 2017
Last Update Submitted That Met QC Criteria
January 2, 2017
Last Verified
January 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0810
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sarcoidosis
-
Mayo ClinicNot yet recruitingCardiac Sarcoidosis | Sarcoidosis, Cardiac | Sarcoidosis With Myocarditis | Sarcoidosis of the HeartUnited States
-
Celularity IncorporatedTerminatedStage 2 Pulmonary Sarcoidosis | Stage 3 Pulmonary SarcoidosisUnited States
-
Vanderbilt UniversityNational Heart, Lung, and Blood Institute (NHLBI)CompletedSarcoidosis; Antimycobacterial TherapyUnited States
-
Duke UniversityFoundation for Sarcoidosis ResearchRecruiting
-
Sanjay Gandhi Postgraduate Institute of Medical...RecruitingSarcoidosis Lung | Pulmonary SarcoidosisIndia
-
Alexandria UniversityCompletedEndobronchial Mucosal Pathology in Pulmonary SarcoidosisEgypt
-
Heart Center Leipzig - University HospitalRecruiting
-
British Columbia Cancer AgencyApproved for marketing
-
University of Maryland, BaltimoreMallinckrodtCompleted
-
University of PennsylvaniaAdvanced Accelerator ApplicationsCompleted
Clinical Trials on Cup forceps
-
Assistance Publique - Hôpitaux de ParisNot yet recruiting
-
Camlıca Erdem HospitalCompleted
-
Oslo University HospitalUniversity of OsloCompleted
-
Ain Shams UniversityNot yet recruitingEndotracheal Tube Wrongly Placed During Anesthetic ProcedureEgypt
-
Sahlgrenska University Hospital, SwedenCompletedProsthesis LooseningSweden
-
Plovdiv Medical UniversityCompletedTooth Extraction Status NosBulgaria
-
University of GuelphAgriculture and Agri-Food Canada; Saskatchewan Pulse GrowersCompleted
-
Uppsala UniversityThe Swedish Research CouncilCompleted
-
DePuy OrthopaedicsCompletedArthritis | Osteoarthritis | Rheumatoid Arthritis | Avascular Necrosis | Acute FractureUnited States
-
Lithuanian University of Health SciencesCompleted